ArticleInternational urology and nephrology2026
Visceral fat measured with CT helps predict recurrence-free survival in patients with localized clear cell renal cell carcinoma.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Critical appraisal of the prognostic value of relative visceral fat area in localized clear cell renal cell carcinoma.Annals of medicine and surgery (2012) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo investigate the prognostic significance of visceral fat to predict recurrence-free survival in patients with localized clear cell renal cell carcinoma (ccRCC).
methodsThis study included patients with localized ccRCC who had undergone curative surgery. Visceral, subcutaneous fat and the relative visceral fat area (rVFA) were quantified utilizing preoperative CT images. The association between rVFA and recurrence-free survival (RFS) was explored using restricted cubic splines, Cox proportional hazards regression, and Kaplan-Meier survival analysis. The predictive capability of rVFA was evaluated using the Boruta algorithm, a predictive model was developed using the random survival forest (RSF) with results visualized via Shapley additive explanations (SHAP).
resultsFour hundred and forty six patients were included. The follow-up median duration was 48.5 months, during which 57 patients experienced metastasis or death. Restricted cubic spline model revealed a nonlinear association between rVFA and tumor progression, exhibiting a U-shaped curve trend with an inflection point at 0.40. Beyond this threshold, rVFA was significantly correlated with an increased risk of progression. The RSF model yielded an area under the curve (AUC) of 0.89 for predicting 1-year RFS, 0.73 for 3-year RFS, and 0.75 for 5-year RFS. Both Boruta and SHAP analyses identified rVFA as a significant predictive feature.
conclusionsA U-shaped association between rVFA and risk of tumor recurrence was observed among patients with ccRCC. A high rVFA is significantly correlated with an increased risk of adverse events, thus indicating that rVFA is a potential indicator for predicting the prognosis of ccRCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.